117
Participants
Start Date
April 25, 2018
Primary Completion Date
December 28, 2022
Study Completion Date
February 19, 2023
CPI-006
Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
CPI-006 + ciforadenant
Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
CPI-006 + pembrolizumab
Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
CPI-006
Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
CPI-006 + ciforadenant
Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
CPI-006 + pembrolizumab
Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
St. Vincent's Hospital, Darlinghurst
Lifehouse, Camperdown
Westmead, Westmead
Monash Hospital, Clayton
Royal Brisbane, Herston
Icahn School of Medicine at Mount Sinai, New York
NY Hematology, Albany
Roswell Park Cancer Institute, Buffalo
UPMC Hillman, Pittsburgh
The John Hopkins University, Baltimore
Virginia Cancer, Fairfax
Carolina BioOncology Institute, Huntsville
Greenville, Greenville
University of Miami, Miami
Sarah Cannon Research Institute, Nashville
Oncology Hematology Care, Cincinnati
Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Northwestern University, Chicago
The University of Chicago, Chicago
University of Oklahoma - Stephenson Cancer Center, Oklahoma City
Mary Crowley Cancer Research, Dallas
Arizona Oncology, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
City Of Hope, Duarte
UC San Francisco, San Francisco
Yale School of Medicine, New Haven
Dana Farber, Boston
Lead Sponsor
Corvus Pharmaceuticals, Inc.
INDUSTRY